A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in later stages of the disease.
Category: Grail Inc
-
A Cancer Detection Test Fails in Major Study
The New York Times – Business: -
Lina Khan’s F.T.C. Secures a Big Win
An appeals court ruling that validated its fight against a deal by the gene-sequencing giant Illumina is a boost for the agency’s expansive antitrust strategy.
-
Gene-Sequencing Company Illumina to Sell Cancer Test Developer
The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.
-
JPMorgan Seeks to Settle Lawsuit by Jeffrey Epstein Victims
After weeks of embarrassing disclosures, the Wall Street giant reached a tentative settlement with the convicted sex offender’s victims.
-
Apple Bets the Vision Pro Can Take the Metaverse Mainstream
The iPhone maker is making a bold bet that it can redefine the niche category of virtual reality with its $3,500 goggles.
-
Hundreds Were Mistakenly Told They Might Have Cancer, Test Company Says
Grail, which makes a blood test for cancer, said a vendor’s software issue caused inaccurate letters to be sent to about 400 customers last month.
-
It’s Not All Bad News for Trump Ahead of His Arraignment
The former president’s poll ratings and some of his business fortunes have rallied ahead of his arraignment on Tuesday.
-
F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition
The New York Times – Business:The move by the commission is seen as a test of regulators’ efforts to prevent big companies from buying small innovators.